undamentalytics Newsletter
Sign in

Exozymes Inc. (EXOZ) stock

Add to watchlist

Add holding +

NASDAQ: EXOZ Nasdaq Biotechnology

Exozymes Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 2 selling5 purchases and 3 sales by directors and officers, last 12 monthsInsider trades
  • Funds6 adding, 1 cuttingOf 0 active managers that changed their stake, 0 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Exozymes Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Volatile shares. Over the past year the shares showed annualised volatility of 78% and a beta of 1.0 against the S&P 500.

Price chart

  • 1 day+9.4%
  • 1 week+20.5%
  • 1 month-21.7%
  • This year-58.5%
  • 1 year-68.6%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Exozymes Inc. valuation models and calculator

No model value for Exozymes Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Valuation models

We value Exozymes Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.9%: the 10-year Treasury yield (4.9%) plus a beta of 1.1 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no twelve-month earnings or share count in the filings yet
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: no twelve-month earnings or share count in the filings yet
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: no twelve-month earnings or share count in the filings yet
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. — Does not apply: no twelve-month earnings or share count in the filings yet
Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. — No model applies: the filings don’t yet support a value.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Exozymes Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$1.19 −9% — —
Next −$1.12 +6% $540000 0%

Positioning

Short interest
0.4%
of tradable shares
Days to cover
1.92
at average volume
Short interest, 1 month
−14%
to October 15, 2026
Held by institutions
1%
of shares
Held by insiders
65.4%
of shares
Employees
32
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 20252026 to date
Return
EXOZ−34%−59%
Industry peers (median)−5%−26%
S&P 500+18%+11%
Months that ended higher
EXOZ58%27%
S&P 50075%46%
Largest fall from a high during the year
EXOZ−53%−68%
S&P 500−19%−9%

Worst fall since November 13, 2024: 82% from December 26, 2024 to October 26, 2026. Getting back needed a 447% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$3.75 – $16.50
From 52-week high
−72.6%
vs 50-day average
−19.6%
vs 200-day average
−41.6%
Volatility (1 year)
79%
Beta vs S&P 500
0.98

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms . Generated November 3, 2026. Definitions in our methodology.

Who owns it

Funds buying and selling
Reported value
$1M
Institutions reporting
9
Shares held vs prior quarter
▲ 97.6%
Positions opened / closed
2 / 0

Top buyers and sellers, Q2 2026: 6 institutions bought and 1 sold ; the biggest buyer was Vanguard Capital Management LLC (+33K shares) and the biggest seller Tower Research Capital LLC (TRC) (−968). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Vanguard Capital Management LLC $463,524 55K 44.2% ▲ 147.8%
Davidson Kahn Capital Management, LLC $210,750 25K 20.1% New
Geode Capital Management, LLC $197,312 23K 18.8% ▲ 6.9%
Blackrock, Inc. $81,012 10K 7.7% ▲ 41.4%
Vanguard Fiduciary Trust Co $79,461 9K 7.6% 0.0%
Morgan Stanley $10,538 1K 1.0% 0.0%
Tower Research Capital LLC (TRC) $2,942 0K 0.3% ▼ 73.5%
UBS Group AG $1,711 0K 0.2% ▲ 745.8%
Barclays PLC $632 0K 0.1% New

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Exozymes Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $6,405 5 trades by 1 insider, last 12 months Insider sales History → $34,854 3 trades by 2 insiders · 0% under pre-set plans
Net ▼ $28,449 net selling
Insider Date Trade Shares Price Value
Perriman Damien Alan Chief Commercial Officer October 12, 2026 Sell 3,729 $5.21 $19,427
Heltzen Michael Chief Executive Officer August 26, 2026 Buy 4 $7.58 $30
Heltzen Michael Chief Executive Officer August 26, 2026 Buy 250 $7.60 $1,900
Heltzen Michael Chief Executive Officer August 26, 2026 Buy 251 $7.35 $1,845
Heltzen Michael Chief Executive Officer August 25, 2026 Buy 250 $7.52 $1,880
Heltzen Michael Chief Executive Officer August 25, 2026 Buy 100 $7.50 $750
Korman Tyler Paz Chief Scientific Officer April 9, 2026 Sell 750 $10.53 $7,897
Korman Tyler Paz Chief Scientific Officer April 8, 2026 Sell 750 $10.04 $7,530

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Recent SEC filings

Data status

When each part of this page on Exozymes Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Exozymes Inc. in brief

What does Exozymes Inc. do?
Exozymes Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Exozymes Inc.'s stock ticker?
Exozymes Inc. trades under the ticker EXOZ on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Exozymes Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Vanguard Capital Management LLC, Davidson Kahn Capital Management, LLC and Geode Capital Management, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Are insiders buying or selling Exozymes Inc. stock?
Over the last 12 months, Exozymes Inc.'s directors and officers reported 5 open-market purchases and 3 sales on Form 4. The insider trading page charts every trade.